Safety and persistence of genetically modified T-cells in patients with non-Hodgkin lymphoma

• Project/Area Number: 26430168
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Jichi Medical University
• Principal Investigator: OHMINE KEN 自治医科大学, 医学部, 准教授 (90316521)
• Co-Investigator(Kenkyū-buntansha): 塚原 智典 自治医科大学, 医学部, 講師 (10362120)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 遺伝子改変T細胞療法 / CD19抗原 / 非ホジキンリンパ腫 / 細胞疲弊化 / 細胞老化

Outline of Final Research Achievements

We are conducting a clinical trial to evaluate the safety and efficacy of administering CD19 specific CAR-Ts manufactured from a patient’s autologous T-cells to combat relapsed or refractory B-cell non-Hodgkin lymphomas. We established a protocol to manufacture a sufficient number of CAR-Ts stimulated by OKT3 onto Retronectin-coated substratum. We demonstrated small scale test using patient’s blood. The patients’ T-cells showed much lower fold expansion compared to healthy donors’. The gene transfer efficiency of patient’s T-cells was equivalent to that of healthy donors. Enrollment started in December 2014. All of seven patients had successful CAR-T production, and three patients safely received an infusion. Although clinically relevant responses seen, PCR analyses failed to show the presence of CAR-Ts in one patient. There remains a need for new therapeutic modalities. These early experiences demonstrate the feasibility and significant clinical impact of CAR-T therapy.

Research Products

• [Journal Article] Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease (2018)
  • Author(s): Kawasaki Yasufumi、Sato Kazuya、Hayakawa Hiroko、Takayama Norihito、Nakano Hirofumi、Ito Ryoji、Mashima Kiyomi、Oh Iekuni、Minakata Daisuke、Yamasaki Ryoko、Morita Kaoru、Ashizawa Masahiro、Yamamoto Chihiro、Hatano Kaoru、Fujiwara Shin-ichiro、Ohmine Ken、Muroi Kazuo、Kanda Yoshinobu
  • Journal Title: Biology of Blood and Marrow Transplantation Volume: 印刷中 Issue: 8 Pages: 1563-1574
  • DOI: 10.1016/j.bbmt.2018.04.016
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement (2018)
  • Author(s): Umino Kento、Fujiwara Shin-ichiro、Ikeda Takashi、Toda Yumiko、Ito Shoko、Mashima Kiyomi、Minakata Daisuke、Nakano Hirofumi、Yamasaki Ryoko、Kawasaki Yasufumi、Sugimoto Miyuki、Yamamoto Chihiro、Ashizawa Masahiro、Hatano Kaoru、Sato Kazuya、Oh Iekuni、Ohmine Ken、Muroi Kazuo、Kanda Yoshinobu
  • Journal Title: Hematology Volume: 印刷中 Issue: 8 Pages: 470-477
  • DOI: 10.1080/10245332.2018.1446279
  • Peer Reviewed
• [Journal Article] A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH (2018)
  • Author(s): Minakata Daisuke、Sato Kazuya、Ashizawa Masahiro、Hatano Kaoru、Oh Iekuni、Fujiwara Shin-ichiro、Ohmine Ken、Kawata Hirotoshi、Muroi Kazuo、Miura Ikuo、Kanda Yoshinobu、et al
  • Journal Title: Cancer Genetics Volume: 220 Pages: 44-48
  • DOI: 10.1016/j.cancergen.2017.11.007
  • Peer Reviewed
• [Journal Article] キメラ抗原受容体T細胞療法 (2018)
  • Author(s): 永山 隆史、大嶺 謙
  • Journal Title: 最新医学 Volume: 73 Pages: 83-91
• [Journal Article] Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia (2017)
  • Author(s): Fujiwara Shin-ichiro、Shirato Yuya、Minakata Daisuke、Nakano Hirofumi、Morita Kaoru、Yamasaki Ryoko、Kawasaki Yasufumi、Sugimoto Miyuki、Ashizawa Masahiro、Yamamoto Chihiro、Hatano Kaoru、Sato Kazuya、Oh Iekuni、Ohmine Ken、Muroi Kazuo、Kanda Yoshinobu、et al
  • Journal Title: International Journal of Hematology Volume: 107 Issue: 6 Pages: 712-715
  • DOI: 10.1007/s12185-017-2378-y
  • Peer Reviewed
• [Journal Article] Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial (2017)
  • Author(s): Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I,Matsuda A, Aoki M, Ito K, Shibayama H.
  • Journal Title: Int J Hematol. Volume: 107 Issue: 3 Pages: 327-336
  • DOI: 10.1007/s12185-017-2353-7
  • Peer Reviewed / Open Access
• [Journal Article] Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia (2017)
  • Author(s): Minakata Daisuke、Fujiwara Shin-ichiro、Ikeda Takashi、Toda Yumiko、Ito Shoko、Mashima Kiyomi、Umino Kento、Nakano Hirofumi、Yamasaki Ryoko、Morita Kaoru、Kawasaki Yasufumi、Sugimoto Miyuki、Yamamoto Chihiro、Ashizawa Masahiro、Hatano Kaoru、Sato Kazuya、Oh Iekuni、Ohmine Ken、Muroi Kazuo、Kanda Yoshinobu
  • Journal Title: International Journal of Hematology Volume: 106 Issue: 3 Pages: 411-417
  • DOI: 10.1007/s12185-017-2251-z
  • Peer Reviewed
• [Journal Article] Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. (2017)
  • Author(s): Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y.
  • Journal Title: Hematology. Volume: 17 Issue: 9 Pages: 1-6
  • DOI: 10.1080/10245332.2017.1312204
  • Peer Reviewed
• [Journal Article] Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia. (2017)
  • Author(s): Ito S, Fujiwara SI, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Ann Hematol. Volume: 96 Issue: 5 Pages: 719-724
  • DOI: 10.1007/s00277-017-2933-x
  • Peer Reviewed
• [Journal Article] High-Dose Methotrexate and Cytarabine-Based Multi-Agent Chemotherapy (Modified Bonn Protocol) for Systemic Lymphoma with CNS Involvement. (2017)
  • Author(s): Umino K, Fujiwara SI, Sato K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Acta Haematol. Volume: 137 Issue: 2 Pages: 93-99
  • DOI: 10.1159/000454890
  • Peer Reviewed
• [Journal Article] CD25 as an adverse prognostic factor in elderly patients with acute myeloid leukemia. (2017)
  • Author(s): Fujiwara SI, Muroi K, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Ozawa K.
  • Journal Title: Hematology Volume: 18 Issue: 6 Pages: 1-7
  • DOI: 10.1080/10245332.2016.1276240
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] ALLに対するCD19を標的としたCAR-T療法 (2017)
  • Author(s): 皆方大祐、大嶺 謙
  • Journal Title: 血液内科 Volume: 75 Pages: 330-337
• [Journal Article] B細胞性造血器腫瘍（白血病・悪性リンパ腫）に対するCD19特異的CAR-T療法の臨床開発 (2017)
  • Author(s): 大嶺 謙、皆方大祐
  • Journal Title: 血液フロンティア Volume: 27 Pages: 961-968
• [Journal Article] キメラ抗原受容体発現Tリンパ球(CAR-T)を用いた養子免疫遺伝子療法 (2017)
  • Author(s): 海野健斗、大嶺 謙
  • Journal Title: 血液疾患最新の治療2017-2019 Volume: - Pages: 51-58
• [Journal Article] A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. (2016)
  • Author(s): Minakata D, Fujiwara SI, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, Ashizawa M, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y
  • Journal Title: Leuk Res. Volume: 42 Pages: 82-87
  • DOI: 10.1016/j.leukres.2015.12.013
  • Peer Reviewed
• [Journal Article] Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. (2016)
  • Author(s): Sugimoto M, Ito S, Mashima K, Umino K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Ashizawa M, Yamamoto C, Fujiwara SI, Okazuka K, Hatano K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kako S, Kanda Y.
  • Journal Title: Ann Hematol. Volume: 95 Issue: 9 Pages: 1513-9
  • DOI: 10.1007/s00277-016-2740-9
  • Peer Reviewed
• [Journal Article] Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. (2016)
  • Author(s): Suzuki T, Kobayashi H, Kawasaki Y, Okazuka K, Hatano K, Fujiwara S, Oh I, Ohmine K, Kanda Y.
  • Journal Title: Int J Hematol Volume: 104 Issue: 4 Pages: 446-53
  • DOI: 10.1007/s12185-016-2046-7
  • Peer Reviewed
• [Journal Article] Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. (2016)
  • Author(s): Yamamoto, C., Ito, S., Mashima, K., Umino, K., Minakata, D., Yamasaki, R., Kawasaki, Y., Sugimoto, M., Nakano, H., Ashizawa, M., Okazuka, K., Hatano, K., Sato, K., Oh, I., Fujiwara S, Ohmine, K., Suzuki, T., Muroi, K., Kanda, Y.
  • Journal Title: Leuk. Lymphoma. Volume: 57 Issue: 11 Pages: 2541-2547
  • DOI: 10.3109/10428194.2016.1153087
  • Peer Reviewed
• [Journal Article] リンパ腫に対するキメラ抗原受容体(CAR)を用いた遺伝子改変T細胞療法 (2016)
  • Author(s): 大嶺 謙
  • Journal Title: 内科 Volume: 117 Pages: 1369-1373
• [Journal Article] CAR-T療法～難治性骨髄腫に対するキメラ抗原受容体発現Tリンパ球を用いた養子免疫遺伝子療法～ (2016)
  • Author(s): 大嶺 謙
  • Journal Title: 多発性骨髄腫 Updating Volume: 9 Pages: 124-135
• [Journal Article] ALLに対するCAR療法 (2016)
  • Author(s): 海野健斗、大嶺 謙
  • Journal Title: 最新医学 Volume: 71 Pages: 50-56
• [Journal Article] Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia. (2016)
  • Author(s): Yamamoto C, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Nakano H, Ashizawa M, Okazuka K, Hatano K, Sato K, Oh I, Fujiwara SI, Ohmine K, Suzuki T, Muroi K, Kanda Y.
  • Journal Title: Leuk Lymphoma. Volume: 25 Pages: 1-7
  • Peer Reviewed
• [Journal Article] The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia. (2016)
  • Author(s): Nakano H, Fujiwara SI, Ito S, Mashima K, Umino K, Minakata D, Yamasaki R, Kawasaki Y, Sugimoto M, Ashizawa M, Yamamoto C, Hatano K, Okazuka K, Sato K, Oh I, Ohmine K, Suzuki T, Muroi K, Kanda Y
  • Journal Title: Hematol Oncol. Volume: in press Issue: 3 Pages: 1-1
  • DOI: 10.1002/hon.2277
  • Peer Reviewed
• [Journal Article] The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies (2015)
  • Author(s): Tsukahara, T., Iwase, N., Kawakami, K., Iwasaki, M., Yamamoto, C., Ohmine, K., Uchibori, R., Teruya, T., Ido, H., Saga, Y., Urabe, M., Mizukami, H., Kume, A., Nakamura, M., Brentjens, R., and Ozawa, K.
  • Journal Title: Gene Therapy Volume: 22 Issue: 2 Pages: 209-215
  • DOI: 10.1038/gt.2014.104
  • Peer Reviewed / Open Access
• [Journal Article] CD19特異的キメラ抗原受容体を発現させたTリンパ球を用いる癌遺伝子治療 (2015)
  • Author(s): 岡塚 貴世志、大嶺 謙
  • Journal Title: 血液フロンティア Volume: 25 Pages: 71-77
• [Journal Article] CD19特異的CAR発現T細胞を用いた造血器腫瘍の治療 (2015)
  • Author(s): 海野 健斗、大嶺 謙
  • Journal Title: 血液内科 Volume: 71 Pages: 493-499
  • NAID: 40020643080
• [Journal Article] 難治性B細胞性造血器腫瘍に対するCD19特異的キメラ抗原受容体(CAR)遺伝子治療は今後の細胞免疫療法の行方を占うか？ (2015)
  • Author(s): 大嶺 謙
  • Journal Title: 内科 Volume: 116 Pages: 1-1
• [Journal Article] Central retinal vein occlusion caused by hyperviscosity syndrome in a young patient with Sjögren's syndrome and MALT lymphoma. (2015)
  • Author(s): Yoshida A, Watanabe M, Ohmine K, Kawashima H.
  • Journal Title: Int Ophthalmol. Volume: 35 Issue: 3 Pages: 429-32
  • DOI: 10.1007/s10792-015-0056-8
  • Peer Reviewed
• [Journal Article] パノビノスタット (2015)
  • Author(s): 大嶺 謙
  • Journal Title: 最新医学 別冊 診断と治療のABC 血液領域の分子標的治療薬 Volume: 102 Pages: 187-196
• [Journal Article] Mechanisms of resistance to azacitidine in human leukemia cell lines. (2014)
  • Author(s): Sripayap P, Nagai T, Uesawa M, Kobayashi H, Tsukahara T, Ohmine K, Muroi K, Ozawa K.
  • Journal Title: Exp Hematol. Volume: 42 Issue: 4 Pages: 294-306
  • DOI: 10.1016/j.exphem.2013.12.004
  • Peer Reviewed
• [Journal Article] Cancer gene therapy using mesenchymal stem cells. (2014)
  • Author(s): Uchibori R, Tsukahara T, Ohmine K, Ozawa K.
  • Journal Title: Int J Hematol. Volume: 99 Issue: 4 Pages: 377-82
  • DOI: 10.1007/s12185-014-1537-7
  • Peer Reviewed
• [Journal Article] Intrathecal administration of high-titer cytomegalovirus immunoglobulin for cytomegalovirus meningitis. (2014)
  • Author(s): Fujiwara S, Muroi K, Tatara R, Ohmine K, Matsuyama T, Mori M, Nagai T, Ozawa K.
  • Journal Title: Case Rep Hematol. Volume: 2014 Pages: 1-3
  • DOI: 10.1155/2014/272458
  • Peer Reviewed
• [Journal Article] Effect of Intra-Medullar and Intra-Venous Infusions of Mesenchymal Stem Cells on Cell Engraftment by In-Vivo Cell Tracking and Osteoinductivity in Rabbit Long Bones: A Pilot Study. (2014)
  • Author(s): Ishihara A, Ohmine K, Weisbrode SE, Bertone AL.
  • Journal Title: Orthop Muscular Syst. Volume: 3 Issue: 03 Pages: 1-5
  • DOI: 10.4172/2161-0533.1000172
  • Peer Reviewed / Open Access
• [Journal Article] 身近な話題・世界の話題 急性リンパ球性白血病に対するCD19特異的キメラ抗原受容体を用いた遺伝子治療(解説) (2014)
  • Author(s): 大嶺 謙
  • Journal Title: 血液フロンティア Volume: 24 Pages: 608-614
• [Presentation] キメラ抗原受容体導入T細胞を用いた B細胞性造血器腫瘍に対する免疫細胞療法の臨床開発 (2018)
  • Author(s): 大嶺 謙
  • Organizer: 第17回日本再生医療学会総会
  • Invited
• [Presentation] CAR-T療法の実際と問題点 (2018)
  • Author(s): 大嶺 謙
  • Organizer: バイオロジクスフォーラム 第15回 学術集会
  • Invited
• [Presentation] Clinical development of CAR-T Therapy for Multiple Myeloma (2017)
  • Author(s): Ken Ohmine, Ryosuke Uchibori, Keiya Ozawa
  • Organizer: 第73回日本血液学会学術集会
  • Invited
• [Presentation] Clinical development of adoptive immunotherapy with Chimeric Antigen Receptor-modified T-cells in patients with Multiple Myeloma (2017)
  • Author(s): Ken Ohmine
  • Organizer: 1st Annual AMN Summit
  • Int'l Joint Research / Invited
• [Presentation] Clinical development of adoptive immunotherapy with CD19-specific chimeric antigen receptor-modified T-cells in patients with B-cell malignancy (2016)
  • Author(s): Ohmine, K.
  • Organizer: The 29th Annual and International Meeting of Japanese Association for Animal Cell Technology
  • Place of Presentation: 神戸国際会議場(兵庫県神戸市)
  • Year and Date: 2016-11-09
  • Int'l Joint Research / Invited
• [Presentation] Factor XIII deficiency deteriorates bleeding symptom in a patient with anti-factor XI inhibitor. (2016)
  • Author(s): 大嶺謙、窓岩清治、畑野かおる、尾崎司、 惣宇利正善、一瀬白帝、大森司、 坂田洋一、村田満、神田善伸
  • Organizer: 第78回日本血液学会学術集会
  • Place of Presentation: パシフィコ横浜(神奈川県横浜市)
  • Year and Date: 2016-10-13
• [Presentation] Clinical development of CD19-CAR therapy in patients with B-cell malignancy (2016)
  • Author(s): 大嶺 謙
  • Organizer: 第22回日本遺伝子細胞治療学会学術集会
  • Place of Presentation: 虎ノ門ヒルズフォーラム(東京都港区)
  • Year and Date: 2016-07-28
  • Invited
• [Presentation] 再発・難治性非ホジキンリンパ腫に対するCD19特異的キメラ抗原受容体(CAR)療法 (2016)
  • Author(s): 大嶺 謙
  • Organizer: 第20回日本がん免疫学会総会
  • Place of Presentation: 大阪国際交流センター(大阪府大阪市)
  • Year and Date: 2016-07-27
  • Invited
• [Presentation] Phase Ⅰ/Ⅱ trial of CD19 Chimeric Antigen Receptor T-cell therapy in patients with relapsed and refractory Non-Hodgkin lymphoma. (2016)
  • Author(s): Ohmine, K.
  • Organizer: 第7回JSH国際シンポジウム
  • Place of Presentation: 淡路夢舞台国際会議場(兵庫県淡路市)
  • Year and Date: 2016-05-13
  • Int'l Joint Research / Invited
• [Presentation] CD19特異的キメラ抗原受容体(CAR)療法の臨床試験. (2016)
  • Author(s): 大嶺 謙
  • Organizer: 第64回日本輸血・細胞治療学会総会
  • Place of Presentation: 国立京都国際会館(京都府京都市)
  • Year and Date: 2016-04-28
  • Invited
• [Presentation] 産学協同によるCAR-T療法の開発 (2016)
  • Author(s): 大嶺 謙
  • Organizer: 第38回日本造血細胞移植学会総会
  • Place of Presentation: 名古屋
  • Year and Date: 2016-03-05
  • Invited
• [Presentation] Adoptive immunotherapy with CD19-specific chimeric antigen receptor-modified T Cells (2015)
  • Author(s): 大嶺 謙
  • Organizer: 第74回日本癌学会学術総会
  • Place of Presentation: 名古屋
  • Year and Date: 2015-10-09
  • Invited
• [Presentation] CD19特異的キメラ抗原受容体(CAR)発現T細胞を用いた養子免疫療法の臨床開発 (2015)
  • Author(s): 大嶺 謙
  • Organizer: 第7回血液疾患免疫療法研究会学術集会
  • Place of Presentation: 東京
  • Year and Date: 2015-09-26
  • Invited
• [Presentation] CD19 特異的CAR発現Tリンパ球を用いた悪性リンパ腫に対する遺伝子治療 (2015)
  • Author(s): 大嶺 謙
  • Organizer: 第55回日本リンパ網内系学会総会
  • Place of Presentation: 岡山
  • Year and Date: 2015-07-10
  • Invited
• [Presentation] CAR-Tを用いたがん免疫遺伝子細胞療法の展開と併用療法への視点 (2015)
  • Author(s): 大嶺 謙
  • Organizer: 第19回日本がん分子標的治療学会学術集会
  • Place of Presentation: 松山
  • Year and Date: 2015-06-12
  • Invited
• [Presentation] CD19特異的キメラ抗原受容体発現Tリンパ球を用いた難治性B細胞性悪性リンパ腫に対する遺伝子治療 (2014)
  • Author(s): 大嶺 謙
  • Organizer: IMSUT-CGCTキックオフ・シンポジウム2014
  • Place of Presentation: 東京
  • Year and Date: 2014-11-21
  • Invited
• [Presentation] Tol2 transposon-based gene transfer of CD19-specific chimeric antigen receptors into human T-cells. (2014)
  • Author(s): Tsukahara T, Iwase N, Yamamoto C, Ohmine K, Uchibori R, Teruya T, Ido H, Urabe M, Mizukami H, Kume A, Nakamura M, Brentjens R, Kawakami K and Ozawa K.
  • Organizer: 第76回日本血液学会学術集会
  • Place of Presentation: 大阪
  • Year and Date: 2014-11-02
• [Presentation] フィラデルフィア染色体陽性急性白血病に対するPSL併用Dasatinib療法の効果と安全性に関する報告 (2014)
  • Author(s): 翁 家国, 多々良 礼音, 藤原 慎一郎, 大嶺 謙, 鈴木 隆浩, 永井 正, 室井 一男, 小澤 敬也
  • Organizer: 第76回日本血液学会学術集会
  • Place of Presentation: 大阪
  • Year and Date: 2014-10-31
• [Presentation] Generation of T-cells expressing a CD19-specific CAR by the Tol2 transposon system. (2014)
  • Author(s): Tsukahara T, Ohmine K, Uchibori R, Urabe M, Mizukami H, Kume A, Nakamura M, Ozawa K.
  • Organizer: 第73回日本癌学会学術総会
  • Place of Presentation: 横浜
  • Year and Date: 2014-09-25
• [Presentation] Tol2 transposon-mediated gene transfer of CD19-CAR to primary human T-cells for the treatment of B-cell malignancies. (2014)
  • Author(s): Tsukahara T, Iwase N, Yamamoto C, Ohmine K, Uchibori R, Takeshi T, Urabe M, Mizukami H, Kume A, Nakamura M, Brentjens R J, Kawakami K, Ozawa K.
  • Organizer: 第20回日本遺伝子治療学会
  • Place of Presentation: 東京
  • Year and Date: 2014-08-08
• [Presentation] B細胞リンパ腫に合併した腫瘍随伴性天疱瘡と考えた1例 (2014)
  • Author(s): 坂口 優, 宮本 有希子, 佐藤 篤子, 藤田 有理香, 小宮根 真弓, 村田 哲, 大槻 マミ太郎, 佐藤 一也, 大嶺 謙, 小澤 敬也
  • Organizer: 第113回 日本皮膚科学会総会
  • Place of Presentation: 京都
  • Year and Date: 2014-05-30
• [Presentation] 細胞療法の現状と将来 キメラ抗原受容体発現Tリンパ球を用いたB細胞性腫瘍に対する遺伝子治療 (2014)
  • Author(s): 大嶺 謙
  • Organizer: 第62回日本輸血・細胞治療学会総会
  • Place of Presentation: 奈良
  • Year and Date: 2014-05-17
  • Invited